TICKERNERD
Menu
HUMAHUMAHealthcare · Biotechnology

HUMA Stock Forecast: Humacyte, Inc. Price Predictions for 2026-2027

Last close, 14 Aug 2026
$0.60
+9.96% on the day

The 5 Wall Street analysts covering Humacyte, Inc. hold a median 12-month price target of $1.25 — +106.7% from the last close. Ticker Nerd's systematic factor model, run across ~4,600 US stocks, ranks it 18 of 100 as at 15 Aug 2026 — in the weakest quartile. The Street sees upside; the factor read is a caution. That gap is the story on this page.

Market cap
$163.1M
Ticker Nerd rank
18 / 100
Median analyst target
$1.25
Analysts covering
5
Total return, dividends reinvested
1W
−15.8%
1M
−14.5%
YTD
−37.1%
1Y
−67.8%
From 52W high
−75.6%
From 52W low
+10.0%
$0.55
$2.48
52-week range, adjusted closes · the dot is the last close
Ticker Nerd rank

HUMA stock analysis: one number for the whole business

Consensus tells you what everyone already believes. The model scores Humacyte, Inc. on its factor families — the same systematic rank behind the Ticker Nerd portfolio.

Where the model ranks itAs at 15 Aug 2026
18 / 100

Percentile across ~4,600 US stocks on Ticker Nerd’s systematic factor model. Higher is better. How the model is built and tested

Size
70
Issuance
61
Accruals
52
Growth
50
Revisions
39
Quality
19
Value
13
Volatility
11
Momentum
3

Size (70): Smaller than most of the companies we track.

Momentum (3): The shares have been drifting down relative to others.

Built and run by Aslam Ghouse, an ex-Goldman Sachs quant trader with fourteen years in markets.

Wall Street

HUMA stock forecast 2026-2027: analyst price targets & predictions

The bullish and bearish analyst opinions on HUMA, reported as data — targets and ratings, the market's view beside the model's.

Share price and the analyst range, 12 monthsAdjusted close, US dollars
$0.00$1.00$2.00$3.00$4.00Oct 25Jan 26Apr 26Jul 26HUMAHigh $4.00Median $1.25Low $1.00

Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.

What Wall Street says5 analysts
4 Buy1 Hold0 Sell
Low $1.00Median $1.25High $4.00

The green dot is the last close — the median target sits +106.7% from it.

Recent analyst actionsNewest first

Of the 20 most recent actions, 1 moved their price target up and 2 moved it down.

DateFirmActionRatingTarget
13 Aug 2026BenchmarkMaintainsSpeculative Buy$2.00 → $1.00
28 July 2026BTIGReiteratesBuy$2.00
28 July 2026BTIGReiteratesBuy—
17 June 2026TD CowenMaintainsBuy—
17 June 2026TD CowenMaintainsBuy$1.50 → $1.25
16 June 2026BTIGReiteratesBuy—
16 June 2026BTIGReiteratesBuy$2.00
11 June 2026HC Wainwright & Co.MaintainsBuy—
11 June 2026HC Wainwright & Co.MaintainsBuy$3.00 → $4.00
8 June 2026BTIGReiteratesBuy—
1 June 2026BenchmarkMaintainsSpeculative Buy—
26 May 2026HC Wainwright & Co.ReiteratesBuy—
14 May 2026TD CowenMaintainsBuy—
13 May 2026BTIGMaintainsBuy—
28 Apr 2026BTIGReiteratesBuy—
28 Apr 2026D. Boral CapitalMaintainsBuy—
24 Apr 2026D. Boral CapitalMaintainsBuy—
21 Apr 2026D. Boral CapitalMaintainsBuy—
8 Apr 2026BarclaysMaintainsOverweight—
31 Mar 2026BenchmarkDowngradeSpeculative Buy—

Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.

Market Radar

This page is one stock. Monday covers all of them.

Computed off the Friday close and sent before the US open.

Market Radar reports the week’s largest rank changes across roughly 4,600 US stocks, the factor behind each one, and where the market went. HUMA appears on the weeks it earns a place.

Free, every Monday. Unsubscribe any time.

Estimates

HUMA analyst estimate revisions

Not the forecast itself — the direction analysts are revising it. Revision direction is one of the model's factor families.

Which way the estimates are movingNext fiscal year
Analysts raising
3
Analysts cutting
0
Fundamentals

Humacyte, Inc. (HUMA) financial data

A margin means little on its own. Each bar marks where the figure sits across the whole US universe we score.

Valuation
Trailing P/E
−2.3×

Cheaper than 86% of US stocks

Price / sales
76.9×

Cheaper than 5% of US stocks

Price / book
11.6×

Cheaper than 9% of US stocks

EV / EBITDA
−1.2×

Cheaper than 68% of US stocks

Growth & margins
Revenue growth (YoY)
34.9%

Higher than 81% of US stocks

Earnings growth (YoY)
−4.3%

Higher than 31% of US stocks

Gross margin
−311.7%

Higher than 1% of US stocks

Operating margin
−6649.3%

Higher than 2% of US stocks

Net margin
−376.1%

Higher than 1% of US stocks

Returns & dividend
Return on equity
−547.9%

Higher than 2% of US stocks

Return on assets
−49.9%

Higher than 8% of US stocks

Dividend yield
—

Bars mark the percentile across the ~4,600 US stocks Ticker Nerd covers, among those reporting the figure.

Peers

HUMA vs competitors

The nearest names by industry and size, scored by the same model — like for like.

Its peer group, ranked by the same modelBiotechnology
CompanyMarket capTKN rank
HUMAHumacyte, Inc.$163.1M
18
OKUROnKure Therapeutics, Inc.$161.1M
55
CNTBConnect Biopharma Holdings Ltd.$160.6M
20
NKTXNkarta, Inc.$166.1M
40
ARMPArmata Pharmaceuticals, Inc.$167.0M
66
CDXSCodexis, Inc.$167.8M
70
TNYATenaya Therapeutics, Inc.$157.6M
40

Look up any of the roughly 4,600 stocks we score.

The rank is the raw material. Whether the rules would actually own Humacyte, Inc. — and when they’d sell — is the membership. See the Ticker Nerd 20 →

News

Latest HUMA news & analysis

Humacyte, Inc. (HUMA) Q2 2026 Earnings Call Transcript

Seeking Alpha · 12 Aug 2026neutral

Humacyte, Inc. (HUMA) released the transcript of its second-quarter 2026 earnings call, covering the company's latest financial and operational update. The transcript, published via Seeking Alpha, provides a record of management's remarks and discussion from the call.

Why it matters — A HUMA watcher would care because the earnings-call transcript offers detailed insight into the company's most recent performance and management commentary during the quarter.

Humacyte, Inc. (HUMA) Reports Q2 Loss, Misses Revenue Estimates

Zacks Investment Research · 12 Aug 2026negative

Humacyte reported a second-quarter loss of $0.16 per share, wider than the Zacks Consensus Estimate of a $0.10 loss but an improvement from the $0.24 per share loss a year earlier. Revenue fell short of estimates.

Why it matters — The wider-than-expected loss and revenue miss indicate quarterly performance below analyst expectations, which is directly relevant for those tracking HUMA's financial progress.

Humacyte Q2 Earnings Call Highlights

MarketBeat · 12 Aug 2026positive

Humacyte reported second-quarter commercial sales growth for its SYMVESS vascular repair product and outlined plans to submit a supplemental biologics license application for dialysis access, as well as begin a first-in-human coronary bypass study.

Why it matters — A HUMA watcher would care because the company is advancing its pipeline with both near-term regulatory steps (dialysis access) and longer-term clinical expansion (coronary bypass) while already showing sales growth for its lead product.

Humacyte Announces Second Quarter 2026 Financial Results and Provides Business Update

GlobeNewsWire · 12 Aug 2026positive

Humacyte reported second quarter 2026 financial results and provided a business update, highlighting breakthrough results from its V012 dialysis access Phase 3 study in which ATEV outperformed AV fistula. The company plans to file a supplemental Biologic License Application (sBLA) for dialysis access with the FDA during the second half of 2026.

Why it matters — The positive Phase 3 dialysis access results and planned sBLA submission signal a potential regulatory expansion for ATEV, a key development for HUMA investors tracking the product pipeline.

Humacyte Investigation Continued: Kahn Swick & Foti, LLC Continues to Investigate the Officers and Directors of Humacyte, Inc. - HUMA

Business Wire · 10 Aug 2026negative

Kahn Swick & Foti, LLC announced it is continuing an investigation into the officers and directors of Humacyte, Inc. The investigation follows the company's August 9, 2024 announcement that the FDA will require additional time to complete its review of the Biologic License Application for its acellular tissue-engineered vessel.

Why it matters — HUMA watchers would care because an ongoing legal investigation into company leadership and a delayed FDA review could add uncertainty around the company and its regulatory timeline.

FAQ

Frequently asked questions about HUMA stock

What is the HUMA stock price forecast for 2026-2027?

The 5 Wall Street analysts covering Humacyte, Inc. have a median 12-month price target of $1.25, with estimates ranging from $1 to $4. These are third-party analyst estimates, not Ticker Nerd forecasts, and they are frequently wrong.

Is HUMA stock a buy right now?

Of the 5 analysts covering Humacyte, Inc., 4 rate it a Buy, 1 a Hold and 0 a Sell. Ticker Nerd's systematic factor model ranks Humacyte, Inc. 18 out of 100 across roughly 4,600 US stocks as at 15 Aug 2026. None of this is personal advice — it does not consider your circumstances.

How does Ticker Nerd's model rank HUMA?

As at 15 Aug 2026, Humacyte, Inc. ranks 18 out of 100 on Ticker Nerd's systematic factor model — a percentile across roughly 4,600 US stocks, built from its factor families. Its strongest factor family is Size (70 of 100).

Will HUMA stock go up?

No one can know that. What the data says: the median 12-month target from 5 analysts implies +106.7% from the last close, and Ticker Nerd's factor model ranks Humacyte, Inc. 18 out of 100 as at 15 Aug 2026. Analyst targets are third-party estimates and frequently wrong; none of this is personal advice.

What is the HUMA stock forecast for 2030?

No analyst covering Humacyte, Inc. publishes a 2030 price target — Wall Street targets run 12 to 18 months out. Sites quoting a 2030 price for HUMA are extrapolating price history, which says nothing about the business. The furthest attributed numbers are the current analyst targets: $1 to $4 over the next 12 months.

How has HUMA stock performed over the past year?

Humacyte, Inc. returned -67.8% over the 12 months to 14 Aug 2026, with dividends reinvested. Past performance does not indicate future returns.

What does Humacyte, Inc. do?

Humacyte, Inc. is a regenerative medicine company developing a pioneering biotechnology platform for universally implantable, off-the-shelf bioengineered human tissues and organs.

What is the latest news on HUMA?

The most recent item we track (Seeking Alpha, 12 Aug 2026): "Humacyte, Inc. (HUMA) Q2 2026 Earnings Call Transcript". Humacyte, Inc. (HUMA) released the transcript of its second-quarter 2026 earnings call, covering the company's latest financial and operational update. The transcript, published via Seeking Alpha, provides a record of management's remarks and discussion from the call.

Company

About Humacyte, Inc.

Humacyte, Inc. is a regenerative medicine company developing a pioneering biotechnology platform for universally implantable, off-the-shelf bioengineered human tissues and organs. These acellular tissue-engineered products aim to treat a broad spectrum of diseases, injuries, and chronic conditions by providing regenerative solutions that minimize immune rejection and infection risks. Key offerings include the Acellular Tissue Engineered Vessel for vascular repair and bypass procedures, such as in vascular trauma, peripheral arterial disease, arteriovenous access for hemodialysis, and pediatric heart surgery. The company also advances organ systems and advanced tissue constructs, including preclinical adaptations for vascularized pancreas constructs, lung constructs, urinary conduits, tracheal, and esophageal replacements. Humacyte supports healthcare professionals with product-related medical information, clinical education, peer-to-peer resources, and operational training for investigational products. Expertise spans regenerative medicine, tissue engineering, biomanufacturing scale-up, decellularization, and preclinical modeling. Founded in 2004 and headquartered in Durham, North Carolina, Humacyte focuses on transforming medical practices through accessible tissue repair and replacement technologies.

CEO Dr. Laura E. Niklason M.D., Ph.D. · 184 employees · United States · https://www.humacyte.com